Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clovis Oncology Inc CLVSQ

Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications... see more

Recent & Breaking News (PINL:CLVSQ)

Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference

Business Wire February 11, 2020

Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France

Business Wire February 3, 2020

Clovis Oncology's Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer

Business Wire January 15, 2020

Clovis Oncology Announces Debt Refinancing Transaction

Business Wire January 7, 2020

Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019

Business Wire January 7, 2020

Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium

Business Wire December 16, 2019

Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy

Business Wire November 13, 2019

Clovis Oncology Announces Third Quarter 2019 Operating Results

Business Wire November 7, 2019

Clovis Oncology to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 7

Business Wire October 22, 2019

Clovis Oncology Announces Rubraca®? (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund

Business Wire October 11, 2019

Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019

Business Wire September 29, 2019

Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals

Business Wire September 23, 2019

Clovis Oncology to Highlight Expanded Data from Rubraca® (rucaparib) TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019

Business Wire September 12, 2019

Clovis Oncology to Present at 2019 Wells Fargo Healthcare Conference

Business Wire August 28, 2019

Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Company's 4.50% Convertible Senior Notes Due 2024

Business Wire August 22, 2019

Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes

Business Wire August 8, 2019

Clovis Oncology to Offer $225 Million of Convertible Senior Notes

Business Wire August 7, 2019

Clovis Oncology Announces Second Quarter 2019 Operating Results

Business Wire August 1, 2019

Clovis Oncology to Announce Second Quarter 2019 Financial Results and Host Webcast Conference Call on August 1

Business Wire July 18, 2019

Clovis Oncology Names Ginger L. Graham as New Board of Directors Chair

Business Wire June 6, 2019